Sodium/potasium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: a new paradigm for development of anti- breast cancer drugs?

2005 ◽  
Vol 96 (1) ◽  
pp. 1-15 ◽  
Author(s):  
Jin-Qiang Chen ◽  
Ruben G. Contreras ◽  
Richard Wang ◽  
Sandra V. Fernandez ◽  
Liora Shoshani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cardiac Glycosides ◽  
Cancer Drugs ◽  
New Paradigm ◽  
Breast Cancer Drugs

scholarly journals Nice Technology Appraisals and the Uptake of Breast Cancer Drugs in the UK

2012 ◽  
Vol 23 ◽  
pp. ix460
Author(s):  
D. Bertwistle ◽  
P. Anderson ◽  
M. Jofre-Bonet
Keyword(s):  
Breast Cancer ◽  
Cancer Drugs ◽  
The Uk ◽  
Breast Cancer Drugs

scholarly journals The comparison of miRNAs that respond to anti-breast cancer drugs and usnic acid for the treatment of breast cancer

2020 ◽  
Vol 72 (6) ◽  
pp. 855-872
Author(s):  
Demet Cansaran-Duman ◽  
Ümmügülsüm Tanman ◽  
Sevcan Yangın ◽  
Orhan Atakol
Keyword(s):  
Breast Cancer ◽  
Usnic Acid ◽  
Cancer Drugs ◽  
Breast Cancer Drugs

scholarly journals Computational evaluation of some compounds as potential anti-breast cancer agents

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Momohjimoh Ovaku Idris ◽  
Stephen Eyije Abechi ◽  
Gideon Adamu Shallangwa
Keyword(s):  
Breast Cancer ◽  
External Validation ◽  
Quantitative Structure Activity Relationship ◽  
New Drugs ◽  
Computational Technique ◽  
Cancer Drugs ◽  
Chemical Structures ◽  
Computational Evaluation ◽  
Derivatives Of ◽  
Breast Cancer Drugs

Abstract Background The emergence of high resistance and toxicity of the existing anti-breast cancer drugs have demanded the need to design new drugs with improved activities against breast cancer. A computational technique incorporating quantitative structure–activity relationship and virtual template-based design was carried out to evaluate thirty-four compounds from derivatives of thiophene, pyrimidine, coumarin, pyrazole and pyridine with anti-breast cancer activities. The chemical structures of the compounds were drawn with chem draw v.12.0.2 and they were optimized using Spartan 14 software. The molecular descriptors were calculated with the aid of PaDel descriptor software. The dataset was curated and then divided into training and test set that was used to generate and validate the model. Results The first out of the four models generated was chosen as the paramount model with statistical validations of R2 = 0.9847, $$R_{{{\text{adj}}}}^{2}$$ R adj 2  = 0.9814, $$Q_{{{\text{cv}}}}^{2}$$ Q cv 2  = 0.9763, min expt. error for non-significant LOF (95%) = 0.0679, an external validation $$R_{{{\text{test}}}}^{2}$$ R test 2 of 0.8240 and coefficient of Y-randomization ($${\text{cR}}_{{\text{p}}}^{2}$$ cR p 2 ) = 0.8200, which confirm the robustness of the model. Conclusions The high predictive power of the generated model describes the models’ reliability and the designed compounds pointed out compound 2 with pGI50 = 4.2504 as the best designed compound to inhibit breast cancer, compared to its co-designed compounds and the template. The results of this research provide vital information to the pharmaceutical chemists and the pharmacologist in the course of developing new breast cancer drugs.

scholarly journals Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs

2019 ◽  
Vol 96 (2) ◽  
pp. 272-296 ◽  
Author(s):  
Mahmud Hasan ◽  
Mohamed Akmal Marzouk ◽  
Saugat Adhikari ◽  
Thomas D. Wright ◽  
Benton P. Miller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Drugs ◽  
Drug Conjugates ◽  
Pharmacokinetic Assessment ◽  
Breast Cancer Drugs

Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6571-6571
Author(s):  
J. Carlos Tapia ◽  
Aida Bujosa Rodríguez ◽  
Consolacion Molto ◽  
Arnoud J. Templeton ◽  
Daniel Shepshelovich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Benefit ◽  
Cancer Drug ◽  
Cancer Drugs ◽  
Curative Intent ◽  
Substantial Clinical Benefit ◽  
Breast Cancer Drugs ◽  
Palliative Setting ◽  
Over Time

6571 Background: The American Society of Clinical Oncology Cancer Research Committee (ASCO-CRC), the ASCO Value Framework Net Health Benefit score version 2 (ASCO-VF), and the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS) are validated tools quantifying the clinical benefit for cancer drugs. Here, we assess the overall survival (OS), quality of life (QoL) and magnitude of clinical benefit of trials supporting breast cancer drug approval by the US Food and Drug Administration (FDA) in the last 25 years. Methods: We searched Drugs@FDA website for all breast cancer drug approvals from January 1, 1995 to December 30, 2020. Drug labels and reports of registration trials were reviewed. We collected data on trial characteristics, efficacy, toxicity and QoL. When more than one study supported a single indication, we preferred efficacy-oriented endpoints (typically OS) to QoL. We excluded trials supporting accelerated-approval indications if these were converted to regular approval during the study period. We scored clinical benefit using the ASCO-CRC in palliative setting, and ASCO-VF and ESMO-MCBS in both curative and palliative setting. Substantial clinical benefit was defined as: OS gains ≥2.5 months and progression-free survival gains ≥ 3 months for ASCO-CRC criteria; ASCO-VF scores ≥ 45 and grade of A or B for trials of curative intent and 4 or 5 for those of non-curative intent using ESMO-MCBS. Trends over time were assessed using Chi-squared test for trend. Results: We identified 51 trials supporting the approval of 32 individual drugs for 51 indications; 12 (24%) were in the curative setting and 39 (76%) in the palliative setting. At the time of approval, 8 (16%) trials reported significant improvement in OS. QoL was reported in 22 trials (43%). Among these, 8 (36%) showed improvement in QoL. For curative intent, we applied ASCO-VF and ESMO-MCBS score to 11 (92%) trials, finding clinical benefit in 10 (91%) and 2 (18%) trials, respectively. In the palliative setting, we used ASCO-CRC, ASCO-VF and ESMO-MCBS scores to rate 32 (82%), 33 (85%) and 38 (97%) trials. Substantial clinical benefit was observed in 20 (63%), 12 (36%) and 7 (19%) trials, respectively. Over time, there has been a decrease in the number of trials supporting approval based on OS (1996-2003 50% vs 2004-12 38% vs 2013-20 13%, P trend = 0.033). There were no statistically significant changes over time in QoL, ASCO-CRC, ASCO-VF and ESMO-MCBS scores. Conclusions: For palliative intent, most trials supporting FDA approval of breast cancer drugs do not meet the ASCO-VF or ESMO-MCBS criteria for substantial clinical benefit. There is substantial inter-framework variability in the assessment of clinical benefit in the curative setting. Over time, there has been a substantial shift towards use of surrogate endpoints as the basis for approval without a clear improvement in substantial clinical benefit.

Abstract P4-15-01: Fragility index of trials supporting approval of breast cancer drugs

2020 ◽  
Author(s):  
Alexandra Desnoyers ◽  
Michelle B. Nadler ◽  
Ramy Saleh ◽  
Eitan Amir
Keyword(s):  
Breast Cancer ◽  
Fragility Index ◽  
Cancer Drugs ◽  
Breast Cancer Drugs
Sign in / Sign up

Export Citation Format

Share Document